Yokohama, Japan

Kaoru Awane

This inventor holds 2 USPTO granted patents. Top assignee: Mitsubishi Chemical Corporation. Active years: 1996-1997.


% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 2

Forward Citations = 135(Granted Patents)


Company Filing History:


Years Active: 1996-1997

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Kaoru Awane: Innovator in Phospholipid Derivatives

Introduction

Kaoru Awane is a notable inventor based in Yokohama, Japan. He has made significant contributions to the field of phospholipid derivatives, holding a total of 2 patents. His work focuses on innovative solutions that enhance the functionality of liposomes in various applications.

Latest Patents

Awane's latest patents include a phospholipid derivative and a liposome containing it. The first patent describes a phospholipid derivative characterized by a specific formula, where A represents a residue of a phospholipid with a phosphatidylethanolamine moiety, and B is a linking group featuring a polyalkylene glycol moiety. The second patent details a phospholipid derivatized with a PEG bifunctional linker, again utilizing the same structural components.

Career Highlights

Kaoru Awane is currently employed at Mitsubishi Chemical Corporation, where he continues to advance his research and development efforts. His work at this esteemed company has allowed him to explore new frontiers in the field of biochemistry and materials science.

Collaborations

Awane collaborates with esteemed colleagues such as Toshiaki Tagawa and Kazuhiro Nagaike. Their combined expertise fosters an environment of innovation and creativity, leading to groundbreaking advancements in their respective fields.

Conclusion

Kaoru Awane's contributions to the field of phospholipid derivatives exemplify the spirit of innovation. His patents and ongoing research at Mitsubishi Chemical Corporation highlight his commitment to advancing scientific knowledge and practical applications.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…